Previous 10 | Next 10 |
2024-03-05 16:01:24 ET More on Cerus Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Financial information for Cerus Read the full article on Se...
Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which managemen...
2024-02-06 10:00:02 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-01-21 16:50:33 ET More on Pacific Biosciences of California, AVITA Medical, etc. AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now Reassessing Pacific Biosciences: Deep...
2024-01-08 09:16:59 ET More on Cerus Cerus GAAP EPS of -$0.04 beats by $0.01, revenue of $39.77M misses by $2.99M Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Financial information for Cerus For further details see: ...
Preliminary Fourth Quarter and Full-Year 2023 Product Revenues of $46.8 million and $156.4 million, respectively 2024 Product Revenues expected to be between $172-$175 million, reflecting 10%-12% growth year over year Cerus Corporation (Nasdaq: CERS) today announced preliminary ...
2024-01-05 13:00:18 ET More on ARK Innovation ETF: ARKK: Not The Beta Play One May Hope For ARKK: Forget About Innovation And Focus On What The U.S. Treasury Does ARKK Set To Ride This Bull Market Higher Into 2024 Cathie Wood's ARK Invest sold 759K shares of ...
2023-11-02 22:52:04 ET Cerus Corporation (CERS) Q3 2023 Earnings Conference Call November 02, 2023 04:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chie...
News, Short Squeeze, Breakout and More Instantly...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss t...
2024-04-12 09:30:05 ET Craig-Hallum analyst issues BUY recommendation for CERS on April 12, 2024 07:19AM ET. CERS was trading at $1.695 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations